Biopharma executives make their predictions for the year ahead, from a bold forecast for the return of the megadeal to a plea ...
The Biden administration has announced the next 15 drugs chosen for Medicare negotiation, marking one of its final acts ...
A little-known mouse protein disrupts cancer-causing chemical changes to genes associated with human colorectal cancer cells ...
Monday, three Big Pharma leaders took center stage and addressed concerns about future patent expirations head-on.
The pharma will spend up to $2.5 billion to acquire an experimental PI3K inhibitor from Scorpion, which will spin out a new ...
Prior experiences include Vice President, Biology, at Zentalis, Head of Epigenetic Drug Discovery at Bristol-Myers Squibb/Celgene and other leading roles in early drug discovery in oncology. Brian ...
The key Ulcerative Colitis therapies expected to launch in the market include Jyseleca (filgotinib), Rinvoq (Upadacitinib), ...
Like a champion boxer on the ropes, Bristol-Myers Squibb (NYSE: BMY) finds itself in a challenging position. Specifically, ...
Multiple Sclerosis companies are Immune Response BioPharma, Clene Nanomedicine, Genzyme, ImStem Biotechnology, Rho, Inc., ...
Researchers have applied AI to every step of the drug development process. But this might not be enough to design safe and ...
Looking at the universe of stocks we cover at Dividend Channel, on 1/3/25, Bristol Myers Squibb Co. (Symbol: BMY), Globe Life Inc (Symbol: GL), and American Express Co. (Symbol: AXP) will all ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback